Literature DB >> 8424580

Beneficial effects of intermittent suction and pressure treatment in intermittent claudication.

J Mehlsen1, H Himmelstrup, B Himmelstrup, K Winther, J Trap-Jensen.   

Abstract

The present study reports on the effects of a physical treatment modality in patients with intermittent claudication. During this treatment a major part of the skin surface is subjected to intermittent suction and pressure. In a previous, preliminary study the authors found a beneficial effect of this treatment in intermittent claudication. The study included 34 patients with moderate, stable intermittent claudication. Twenty-two patients participated in a double-blinded, randomized trial comparing the effects of 25 treatments to 25 placebo applications given over a period of two months. Twelve patients participated in an open trial investigating the possible effects of the treatment on platelet aggregation and fibrinolysis. Pain-free and maximal walking distances were measured on a treadmill, and systolic blood pressure was measured on the upper limb, the ankle, and the first toe bilaterally. The threshold for adenosine diphosphate (ADP)-induced platelet aggregation was tested, and the fibrinolytic activity was estimated from the euglobulin clot lysis time. Active treatment resulted in significant improvements in pain-free and maximal walking distances, whereas no changes could be found during placebo administration. The treatment caused significant increments in the ADP thresholds for platelet aggregation, while the effects on fibrinolysis were uncertain. It is concluded that intermittent suction and pressure treatment offers a new approach for conservative treatment of intermittent claudication.

Entities:  

Mesh:

Year:  1993        PMID: 8424580     DOI: 10.1177/000331979304400103

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  6 in total

1.  Intermittent mild negative pressure applied to the lower limb in patients with spinal cord injury and chronic lower limb ulcers: a crossover pilot study.

Authors:  Øyvind Heiberg Sundby; Ingebjørg Irgens; Lars Øivind Høiseth; Iacob Mathiesen; Eivind Lundgaard; Hanne Haugland; Harald Weedon-Fekjær; Jon O Sundhagen; Gunnar Sandbæk; Jonny Hisdal
Journal:  Spinal Cord       Date:  2018-03-01       Impact factor: 2.772

2.  Intermittent negative pressure applied to the lower limb increases foot macrocirculatory and microcirculatory blood flow pulsatility in people with spinal cord injury.

Authors:  Øyvind Heiberg Sundby; Lars Øivind Høiseth; Ingebjørg Irgens; Iacob Mathiesen; Eivind Lundgaard; Hanne Haugland; Harald Weedon-Fekjær; Jon O Sundhagen; Gunnar Sanbæk; Jonny Hisdal
Journal:  Spinal Cord       Date:  2017-12-28       Impact factor: 2.772

3.  Application of intermittent negative pressure on the lower extremity and its effect on macro- and microcirculation in the foot of healthy volunteers.

Authors:  Øyvind H Sundby; Lars Øivind Høiseth; Iacob Mathiesen; Jørgen J Jørgensen; Harald Weedon-Fekjær; Jonny Hisdal
Journal:  Physiol Rep       Date:  2016-09

4.  The acute effects of lower limb intermittent negative pressure on foot macro- and microcirculation in patients with peripheral arterial disease.

Authors:  Øyvind Heiberg Sundby; Lars Øivind Høiseth; Iacob Mathiesen; Harald Weedon-Fekjær; Jon O Sundhagen; Jonny Hisdal
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

5.  The acute effects of different levels of intermittent negative pressure on peripheral circulation in patients with peripheral artery disease.

Authors:  Henrik Hoel; Lars Øivind Høiseth; Gunnar Sandbaek; Jon Otto Sundhagen; Iacob Mathiesen; Jonny Hisdal
Journal:  Physiol Rep       Date:  2019-10

6.  Effects of intermittent negative pressure treatment on circulating vascular biomarkers in patients with intermittent claudication.

Authors:  Henrik Hoel; Erik Mulder Pettersen; Lars Øivind Høiseth; Iacob Mathiesen; Arne Seternes; Ingebjørg Seljeflot; Jonny Hisdal
Journal:  Vasc Med       Date:  2021-05-13       Impact factor: 3.239

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.